Alto Neuroscience (NYSE:ANRO - Get Free Report) was downgraded by equities research analysts at Wedbush from an "outperform" rating to a "neutral" rating in a research note issued on Wednesday, Marketbeat Ratings reports. They presently have a $4.00 target price on the stock, down from their prior target price of $29.00. Wedbush's price objective points to a potential downside of 8.26% from the stock's previous close.
Several other analysts have also issued reports on ANRO. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating on the stock in a research report on Wednesday. Rodman & Renshaw downgraded shares of Alto Neuroscience from a "buy" rating to a "neutral" rating in a research note on Wednesday. Finally, William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alto Neuroscience has a consensus rating of "Moderate Buy" and a consensus target price of $24.40.
Check Out Our Latest Research Report on Alto Neuroscience
Alto Neuroscience Price Performance
Shares of ANRO stock traded down $10.17 on Wednesday, reaching $4.36. The stock had a trading volume of 16,254,234 shares, compared to its average volume of 335,567. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04. The firm's 50-day moving average is $12.22 and its two-hundred day moving average is $12.48. Alto Neuroscience has a 12 month low of $4.26 and a 12 month high of $24.00.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.07. On average, equities research analysts predict that Alto Neuroscience will post -2.63 earnings per share for the current year.
Institutional Investors Weigh In On Alto Neuroscience
A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. RA Capital Management L.P. bought a new stake in shares of Alto Neuroscience in the 1st quarter worth approximately $21,267,000. Price T Rowe Associates Inc. MD bought a new position in shares of Alto Neuroscience in the 1st quarter valued at about $9,788,000. Vanguard Group Inc. bought a new position in shares of Alto Neuroscience in the 1st quarter valued at about $8,233,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience in the 1st quarter valued at about $7,039,000. Finally, Artal Group S.A. bought a new stake in Alto Neuroscience in the first quarter worth about $5,372,000.
About Alto Neuroscience
(
Get Free Report)
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Read More
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
